Skip to main content
padlock icon - secure page this page is secure

Cyclophosphamide’s addition in relapsed/refractory multiple myeloma patients with biochemical progression during lenalidomide‐dexamethasone treatment

Buy Article:

$59.00 + tax (Refund Policy)

The aim of this study was to evaluate the addition of cyclophosphamide in relapsed‐refractory multiple myeloma patients (RRMM) who experienced biochemical relapse or progression without CRAB, during treatment with lenalidomide and dexamethasone (Rd), to slow down the progression in active relapse.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: biochemical relapse; cyclophosphamide; dexamethasone, lenalidomide; relapsed/refractory multiple myeloma

Document Type: Research Article

Publication date: August 1, 2018

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more